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Invasive zygomycosis rarely complicates trauma. We describe the first recorded case of invasive infection of
the anterior abdominal wall and omentum with the zygomycete Syncephalastrum racemosum, which was suc-
cessfully treated with partial surgical debridement and amphotericin B lipid complex.
CASE REPORT
A 23-year-old previously well male presented with a large
abdominal wound after falling and being impaled on a steel
reinforcing rod.
His abdominal wall was perforated; he had splenic lacera-
tions, mesenteric tears, colon and duodenal perforations, pan-
creatic injury, and an avulsed left renal artery. The visceral
lacerations were repaired, a splenectomy was performed, and a
temporary mesh was interposed in the abdominal wall midline.
Cephazolin and metronidazole were given as prophylactic an-
tibiotics. Eight days later, his abdomen became distended and
the abdominal wall skin appeared necrotic. He was treated
with intravenous antibiotics including vancomycin, mero-
penem, ticarcillin-clavulanate, and fluconazole. Several surgi-
cal procedures were performed and included extensive de-
bridement of the necrotic tissue in the anterior abdominal wall,
omentum, and retroperitoneum.
Syncephalastrum racemosum, Candida glabrata, Enterococcus
faecalis, and Escherichia coli were isolated from the retroper-
itoneal tissue excised at laparotomy. He was commenced on
therapy with amphotericin B lipid complex (Abelcet, Orphan
Australia Pty. Ltd.), 300 mg given intravenously daily. Three
days later, S. racemosum was also isolated from an abdominal
wall swab, abdominal wall skin tissue, and fluid from the left
upper quadrant. Four days thereafter, S. racemosum was again
isolated from skin tissue from the abdominal wall wound mar-
gin and left iliac fossa swab. Nearly a month after the initial
injury, the last positive specimen for S. racemosum was isolated
from omental tissue. A partial omentectomy was performed,
but because of technical difficulty no further debridement was
carried out and clinically infected tissue remained in situ. His-
topathology of the omental tissue confirmed the continuing
presence of characteristic nonseptate hyphae. He was treated
with amphotericin B lipid complex for a total of 29 days,
including 19 days after the last debridement and 15 days after
the last positive specimen for S. racemosum.
Specimens of the retroperitoneal tissue were plated onto
blood and chocolate agar incubated at 35°C in CO2 and plated
to blood agar incubated at 35°C under anaerobic conditions.
After 30 h of incubation, a gray-brown colony of a fungus was
seen on the blood and chocolate agar.
The fungus was plated to Sabouraud’s dextrose agar con-
taining chloramphenicol and gentamicin and incubated at 35°C
in O2. After 24 h of incubation, a rapidly growing white cottony
colony of fungus was evident. A small portion of an isolated
colony was cut out midway between the center and edge of a
colony. The fungi were placed in a drop of lactophenol cotton
blue on a slide, covered with a coverslip, and observed micro-
scopically. Aseptate hyphae branching at right angles as well as
large conidial heads were observed. A 1.5 cm-square of Sab-
ouraud’s agar was cut out of an agar plate and placed in the
middle of an alcohol-clean slide. The sides of the square were
inoculated with the fungus. The slide culture was covered and
incubated at 25°C in a moist chamber. After 2 days the culture
was examined and the formation of recognizable elements
noted. The coverslip was lifted from the agar, passed through
a Bunsen flame, and placed on a drop of lactophenol cotton
blue on a slide. Using a light microscope, the fungus was
examined for sporogenesis or conidiation. Sporangiophores
branching at right angles and terminating in spherical colu-
mella, with cylindrical mesosporangia around the entire cir-
cumference, containing rows of sporangiospores, were ob-
served. The sporangiospores were smooth and appeared dark
brown, as did the merosporangia and terminal vesicles. These
morphological features meet the criteria for S. racemosum
(10). Dark-brown zygospores were also observed. The broad,
ribbon-like, aseptate hyphae were visible on the slide cultures
as well as the histopathology stains (Fig. 1). The wet-mount
microscopy from the cultures (Fig. 2) demonstrates the typical
daisy-head appearance and other morphological features.
Infection remains the greatest risk for victims of penetrating
abdominal injury (3), with Staphylococcus aureus and Enter-
obacteriaceae the most commonly implicated organisms in
traumatic wounds. Streptococcal or clostridial infections may
cause necrotizing fasciitis and clostridial myonecrosis. Unusual
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pathogens, such as Aeromonas hydrophila and Vibrio vulnificus,
have been described. Aggressive and sometimes fatal wound
infections have been reported from zygomycetes and Aspergil-
lus spp. (1). In cases of extensive trauma, inoculation of devi-
talized tissues with soil may initiate infection by zygomycetes,
even in persons whose immunologic status appears to be nor-
mal (11).
Searching the literature with Pubmed, Medline, Cinahl, Pro-
quest, Sciencedirect, Embase, and Web of Science using Syn-
cephalastrum, zygomycosis, zygomycetes, and human disease as
keywords revealed that Syncephalastrum species have not been
described before for a deep posttraumatic wound. In fact, this
organism has not yet been definitively proven as a cause of
human infection. A case of Syncephalastrum fungus ball of the
lung (6) has been reported but is now believed to be Aspergillus
niger (7). The only remaining detailed report published is a
case of cutaneous Syncephalastrum infection in a 50-year-old
diabetic man. The lesion described contained several draining
sinus tracts. In this case, Syncephalastrum was found in soil
samples where the patient worked on a tea plantation in Oota-
camund, India (5). According to Ribes, Vanover-Sams, and
Baker, a previous site of trauma with soil contamination was
suggested by the location of infection on the finger (10). This
patient received no specific treatment for the fungal infection,
although his diabetes was treated. He left the hospital a few
days after admission, and it is reported that he died of diabetes
mellitus in his home town a few months later (5). According to
Ribes, Vanover-Sams, and Baker (10), a case of Syncephalas-
trum isolated from a wound culture was reported by Otcenasek
and Buchta, but no details of the case were provided.
Syncephalastrum has also been isolated from normal finger
and toenail clippings from several Egyptian students who had
no clinical disease (10).
Syncephalastrum racemosum has been found widely in the
environment (10). Until now it has been debated whether this
fungus can actually cause disease in humans. It is usually de-
scribed as having low pathogenic potential in a competent host
and may cause disease only as an opportunistic pathogen (10).
In vivo studies with diabetic rabbits challenged with intranasal
instillations of S. racemosum spores failed to detect pulmonary
or cerebral invasive disease, again suggesting that the virulence
of this organism is quite low (9). According to Weitzman, this
fungus should be suspected to be a pathogen if it is isolated
repeatedly from sterile tissue or body fluids, if fungal structures
are observed in the direct microscopic examination and are
compatible in morphology and color with the fungus isolated
from the specimen, and if the histopathology of the biopsy
specimen indicates tissue invasion (12). This was demonstrated
in this case, therefore definitively diagnosing invasive infection
due to S. racemosum.
Successful therapy for invasive zygomycete infection usually
involves a combined approach consisting of early diagnosis,
correction of the underlying predisposing condition, aggressive
surgical debridement, and early systemic amphotericin ther-
apy. Amphotericin B is the only drug with proven clinical
efficacy (2).
Antifungals tested against S. racemosum to which in vitro
susceptibility has been demonstrated are amphotericin B, ny-
statin, and pimaricin (8). Resistance to saperconazole and other
azoles has been reported (10). The total dose of amphotericin
B required to successfully treat zygomycosis is unknown. A
total dose of at least 2 g has been administered to patients who
have been reported to have recovered in most studies. The
lipid formulation of amphotericin B seems to be as active as
conventional amphotericin B and allows for higher doses to be
administered with acceptable tolerance, up to 10 mg/kg of body
weight/day (4). The described patient was treated with paren-
teral amphotericin B lipid complex at a daily dose of 300 mg (5
mg/kg). Surgical debridement has been described as the key
feature of the management of zygomycosis, because of the
difficulty in eradicating zygomycetes with antifungal therapy
from areas of necrotic tissue (4). Successful treatment of pa-
tients with mucormycosis with antifungal therapy alone has
been described but is clearly the exception, and aggressive
surgical debridement of necrotic tissue is considered the norm
(1). Repeated debridement may be required to remove the
continuously appearing necrotic tissue, and the duration of
antifungal therapy depends on the clinical response of the
infection (1).
FIG. 1. Aseptate hyphae in histopathology stain.
FIG. 2. Wet-mount microscopy of the intraabdominal cultures
demonstrating the features of Syncephalastrum racemosum.
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The importance of this case is that it describes the first
recorded definitively proven case of S. racemosum infection in
a human. S. racemosum was identified from retroperitoneal
tissue, abdominal wall swabs, abdominal wall skin, intraab-
dominal fluid, intraabdominal swabs, and omental tissue. S.
racemosum fungal hyphae invading normal tissue were also
seen in histology.
This infection was successfully treated with partial debride-
ment and amphotericin B lipid complex. S. racemosum was still
present in the omental biopsies collected after the last debride-
ment was done. The patient was kept on high doses of ampho-
tericin B lipid complex (300 mg/day) for a further 15 days. A
total of 8.6 g of amphotericin B lipid complex was given. The
subsequent specimens showed no evidence of the fungus. The
wound healed, and the patient survived.
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